Back to Search
Start Over
Spondyloarthritis-Associated IgA Nephropathy
- Source :
- Kidney International Reports, Kidney International Reports, 2020, 5 (6), pp.813-820. ⟨10.1016/j.ekir.2020.03.012⟩, Kidney Int Rep, vol. 5, no. 6, pp. 813-820, Kidney International Reports, Elsevier, 2020, 5 (6), pp.813-820. ⟨10.1016/j.ekir.2020.03.012⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- International audience; Introduction: IgA nephropathy (IgAN) can be associated with spondyloarthritis (SpA). The course of SpA-associated IgAN remains largely unknown due to the absence of large cohorts.Methods: This retrospective study included patients with biopsy-proven IgAN and definite SpA. Kidney biopsies were centrally examined and scored according to the IgAN Oxford Classification. Thirty-two patients fulfilled the inclusion criteria, with a male:female ratio of 9:1 and median age of 27 and 37 years at SpA and IgAN diagnosis, respectively. HLA-B27 was positive in 90% of cases, and most patients (60%) presented with ankylosing spondylitis. The mean baseline estimated glomerular filtration rate (eGFR) was 84 ± 26 ml/min per 1.73 m2, and the urine protein-to-creatinine ratio was 0.19 g/mmol.Results: Renal biopsy revealed frequent presence of crescents (33%) and interstitial inflammation (18%). Despite almost constant use of renin-angiotensin system inhibitors, combined with steroids in 13 of 32 patients, renal outcome was particularly poor. After a median follow-up of 5.9 years, 4 patients (12.5%) reached end-stage renal disease and 41% of patients experienced a >50% decrease of eGFR. The mean annual eGFR decline rate was -4.3 ± 6.7 ml/min per 1.73 m2. The risk of reaching class IV or V chronic kidney disease (CKD) stage during follow-up was associated with the presence of hypertension, level of proteinuria, and baseline S- and T-scores of the Oxford.Conclusion: SpA-associated IgAN is associated with a poor renal outcome, despite frequent use of steroids. Tumor necrosis factor (TNF)-α blockade did not appear to influence the rate of eGFR decline in this setting.
- Subjects :
- medicine.medical_specialty
renal failure
NSAIDs
030232 urology & nephrology
Renal function
030204 cardiovascular system & hematology
urologic and male genital diseases
Gastroenterology
[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
Nephropathy
03 medical and health sciences
0302 clinical medicine
IgA nephropathy
TNF-alpha blockers
ankylosing spondylitis
spondyloarthritis
Internal medicine
medicine
10. No inequality
Kidney
Ankylosing spondylitis
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Proteinuria
medicine.diagnostic_test
business.industry
TNF-α blockers
Retrospective cohort study
medicine.disease
[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
3. Good health
medicine.anatomical_structure
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Nephrology
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Renal biopsy
medicine.symptom
business
Kidney disease
Subjects
Details
- Language :
- English
- ISSN :
- 24680249
- Database :
- OpenAIRE
- Journal :
- Kidney International Reports, Kidney International Reports, 2020, 5 (6), pp.813-820. ⟨10.1016/j.ekir.2020.03.012⟩, Kidney Int Rep, vol. 5, no. 6, pp. 813-820, Kidney International Reports, Elsevier, 2020, 5 (6), pp.813-820. ⟨10.1016/j.ekir.2020.03.012⟩
- Accession number :
- edsair.doi.dedup.....ca318811d1ecb03730ff6315c6b2e034
- Full Text :
- https://doi.org/10.1016/j.ekir.2020.03.012⟩